August 20, 2023
Skandinaviska Enskilda Banken AB publ Increases Stake in Hologic, Inc.
Skandinaviska Enskilda Banken AB publ (SEB) has recently bolstered its position in medical equipment provider Hologic, Inc. (NASDAQ:HOLX) by 15.2% during the first quarter of this year. This information comes from SEB’s most recent 13F filing with the Securities and Exchange Commission (SEC). The bank now holds a total of 1,010,366 shares of HOLX after acquiring an additional 133,257 shares during the period. Based on its latest SEC filing, SEB owns approximately 0.41% worth of Hologic equating to $81,537,000.
Hologic recently released their quarterly earnings data for the second quarter ending July 31st. The medical equipment provider reported earnings per share (EPS) of $0.93 for the quarter, surpassing analysts’ consensus estimate of $0.89 by $0.04. Additionally, Hologic boasted a return on equity (ROE) of 19.02% and a net margin of 11.99%. In terms of revenue generated during this period, Hologic recorded $984.40 million as opposed to the consensus estimate of $960.22 million given by equity research analysts.
Comparing these figures to the previous year’s second quarter results, it shows that Hologic experienced a slight decrease in revenue by about 1.8%. In the same quarter last year, the company reported an EPS of $0.95 compared to the current EPS results for this year at $0.93.
Looking ahead to fiscal year expectations, equities research analysts predict that Hologic is likely to post an EPS figure of 3.92 for the current fiscal year.
In other news related to Hologic, Director Scott T. Garrett recently conducted a sale of 10,000 shares of the company’s stock on June 15th. The transaction took place at an average price of $79.72, resulting in a total value of $797,200. Following this sale, Garrett now owns 57,039 shares in Hologic, valued at approximately $4,547,149.08. Details concerning this sale were disclosed through a filing with the SEC, which can be accessed via their website. Corporate insiders presently own 1.66% of Hologic’s stock.
About Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ (SEB) is an established financial institution known for its extensive range of banking services and solutions in the Nordic region. With substantial experience and a global presence, SEB offers corporate banking, retail banking, investment banking, asset management, trading operations, and advisory services to various clients worldwide.
As SEB expands its position in Hologic during the initial quarter and secures additional shares of the medical equipment provider’s stock, investors will be keen to see how this strategic investment contributes to SEB’s overall portfolio performance and long-term growth prospects.
(Disclaimer: This article does not provide specific investment advice or endorse any particular investment product or strategy. Readers are encouraged to conduct further research before making any investment decisions.)
[bs_slider_forecast ticker=”HOLX”]
Hologic, Inc. Attracting Attention from Hedge Funds and Institutional Investors; Notable Shareholders Increase Stakes
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”HOLX” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Hologic, Inc., a leading medical equipment provider, has been attracting the attention of various hedge funds and institutional investors. One such investor is Macquarie Group Ltd., which significantly increased its stake in Hologic during the second quarter of this year. Macquarie now owns an impressive 6,284,053 shares of Hologic’s stock, valued at $435,485,000 after acquiring an additional 4,363,687 shares during the period.
Another notable investor is Norges Bank, which purchased a new position in Hologic in the fourth quarter of last year. The value of this position was approximately $175,900,000. Meanwhile, Arrowstreet Capital Limited Partnership saw significant growth in its holdings with Hologic by 110.6% during the first quarter of this year. The firm now possesses 1,896,174 shares of the company’s stock valued at $145,664,000 after adding an additional 995,854 shares to their portfolio.
Victory Capital Management Inc., an investment management company, also grew its holdings in Hologic by 21.3% during the fourth quarter of last year. Victory Capital now owns a substantial amount – 5,174,355 shares – of Hologic’s stock with a value of $387,093,000.
Lastly, Prudential Financial Inc. witnessed remarkable growth in its holdings with Hologic during the first quarter of this year as well – a staggering increase by 246%. Prudential Financial now holds 920 ,718 shares of Hologic’s stock valued at $70 ,730 ,000 after acquiring an additional 654 ,628 shares.
As for trading activity on Friday August 20/2023 , HOLX stock traded down $0 .85 to settle at $73 .15 . The trading volume accumulated to 3 ,844 ,564 shares , compared to its average volume which was reported to be standing at 2, 121,677 shares. Hologic, Inc. demonstrated a current ratio of 4.42 and a quick ratio of 3.73 as well as a debt-to-equity ratio of 0.54.
In terms of yearly performance, Hologic’s stock price experienced fluctuation with a low of $59 .78 and a high of $87 .88 over the past 52 weeks. As for its moving averages, the 50-day moving average price stood at $78 .70 while the 200-day moving average price was reported to be approximately $80.48.
Investment researchers have offered their insights on Hologic, with Raymond James reducing its target price from $100.00 to $95.00 while maintaining an “outperform” rating for the company in a report published on August 1st. StockNews.com provided coverage on Hologic and assigned a “buy” rating for the company in their report published on Friday.
On August 1st, Bank of America also reduced their target price for Hologic from $94.00 to $86 .00 , establishing a “neutral” rating for the company. Morgan Stanley reaffirmed an “equal weight” rating with a target price set at $86 .00 in another report published on August 1st.
Citigroup also expressed its outlook on Hologic by lowering the target price from $90 .00 to $85 .00 and setting it with a “neutral” rating in their recent report published on August 1st.
Overall, out of fifteen research analysts who have assessed Hologic’s stock, six analysts have rated it as “hold,” nine analysts have given it a buy rating, according to Bloomberg.com data. The stock presently enjoys an overall consensus rating of “Moderate Buy” and has an average target price estimated at $88 .92.
To keep track of further developments with regards to this medical equipment provider, interested readers can refer to the latest research report on Hologic. This report offers in-depth analyses and insights into the company’s current status as well as its financial performance.
